Cipla Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1476.6, up 2.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.46% on the day, quoting at 23944.45. The Sensex is at 76716.34, down 0.5%. Cipla Ltd has risen around 6.21% in last one month.

Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 4.4% in last one month and is currently quoting at 24969.5, up 1.25% on the day. The volume in the stock stood at 20.59 lakh shares today, compared to the daily average of 15.8 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1472.9, up 2.22% on the day. Cipla Ltd is down 1.95% in last one year as compared to a 6.16% drop in NIFTY and a 14.71% drop in the Nifty Pharma index.

The PE of the stock is 33.8 based on TTM earnings ending March 26.

Powered by Capital Market - Live News

Cipla announced that ESG Risk Assessments & Insights Limited, a SEBI registered ESG Rating Provider (ESGRisks.ai), has revised the Company's ESG rating from 68 to 64. The revision is based on re-evaluation of publicly available information and certain new information considered during the assessment period.

Cipla will hold a meeting of the Board of Directors of the Company on 23 July 2026.

The target price indicates a potential upside of about 20.23% from the current market price.

The brokerage expects a series of near-term developments to support the stock. These include the anticipated approval of gFlovent from Cipla's Goa facility and the planned launch of gVentolin, both of which could strengthen the company's position in the US market.

The brokerage also highlighted the strong performance of Nintedanib in the US, where the product has captured nearly half of the market. It expects Cipla's US business to return to growth after a period of weakness.

The brokerage said the company's India business remains resilient, supported by a recovery in its respiratory portfolio. It added that a re-inspection of Cipla's Indore manufacturing facility is expected shortly, and a favourable outcome along with USFDA clearance could act as an additional trigger for the stock.

The brokerage further noted that easing geopolitical tensions have reduced concerns over raw material costs and margin pressures.

According to the report, the earnings impact from the decline in gRevlimid-related sales has largely played out, suggesting that Cipla's profit cycle may have bottomed out. The stock is currently valued at around 25 times FY27 estimated earnings and 21 times FY28 estimated earnings.

The brokerage said Cipla offers a compelling combination of domestic pharmaceutical exposure, improving US business prospects and attractive valuations. It noted that the company's India business is valued at 7.8 times FY26 sales, compared with 8.5 times for peer Mankind Pharma, making the risk-reward profile favourable.

Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.

The drug major's consolidated net profit stood at Rs 554.64 crore in Q4 FY26, down 54.61% from Rs 1,221.84 crore in Q4 FY25. Revenue from operations declined 2.02% YoY to Rs 6,464.26 crore in Q4 FY26 from Rs 6,597.72 crore in the year-ago period.

Powered by Capital Market - Live News